Beckman Coulter, Inc.

EMERYVILLE, CA, USA I March 26, 2025 I Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next ​generation RNA precision manufacturing platform, announced today that Chief Executive Officer (CEO) Igor Khandros, Ph.D., is retiring from the company’s top leadership position. Cynthia Collins, a member of the company’s board of directors, has been appointed as the company’s executive chair. Ms. Collins will also serve as interim CEO. Dr. Khandros will remain on Nutcracker Therapeutics’ board of directors. Dr. Khandros co-founded Nutcracker Therapeutics in 2018, alongside Chief Technology Officer Benjamin Eldridge. At the time, the duo recognized the versatility and wide range of applications for RNA, and sought to develop a technology platform, drawing inspiration from the semi-conductor industry, that can take advantage of its innate characteristics to seamlessly design, develop and manufacture RNA-based therapeutics. “We set out to create a fully integrated, cutting edge execution vehicle for the development and manufacturing of personalized RNA therapies, rather than leaving it to an afterthought. The team at Nutcracker Therapeutics has created a platform that integrates device, software and biochemistry innovations, which lead to cost and cycle-time efficiencies, and ensures the timely scaling of this newly emerging class of medicines,” said Dr. Khandros. “As Nutcracker Therapeutics continues to grow and evolve, this appears to be the perfect time to turn over the reins to an accomplished leader with extensive experience in drug development, operations, and commercialization,” Dr. Khandros stated. “Cindy has a deep understanding of the complexities and requirements of a CRDMO, and is uniquely capable of creating a myriad of partnerships which will propel the company and the field forward.” Under the leadership of Dr. Khandros, Nutcracker Therapeutics grew from a startup with a clear vision and mission for the RNA industry to a company that is well-equipped to jumpstart the development of RNA therapeutics, and personalized cancer therapeutics in particular. This has been made possible using its unique, proprietary core technologies — the Nutcracker® Manufacturing Unit (NMU-Symphony™), CodonCracker™ software, and Nutshell® delivery vehicles. Recognizing the provision of CRDMO services to the RNA field as a logical next step, Dr. Khandros guided the company’s evolution in this endeavor last year. “We’re deeply grateful for Igor’s service and dedication to building the company over the last seven years,” commented Cynthia Collins. “His visionary leadership and unwavering dedication to Nutcracker Therapeutics’ founding mission have been instrumental in the company’s success and growth. Under Igor’s guidance, we’ve created revolutionary technologies to enhance the field of RNA and positioned ourselves as a leader in this industry.” Cynthia Collins has been appointed executive chair, as well as interim CEO, of Nutcracker Therapeutics. Ms. Collins has been a member of Nutcracker Therapeutics’ board of directors since April 2023 and is a recognized leader with more than four decades of experience in genetic and cell medicines, biopharmaceuticals, life sciences, and diagnostics. Most recently she was the CEO of Editas Medicine, a premier CRISPR company where she oversaw the first clinical trial administration of an in vivo CRISPR gene editing therapy. Her other notable roles include CEO of Human Longevity, CEO and general manager of various life science businesses at GE Healthcare, CEO of GenVec, group vice president at Beckman Coulter, CEO of Sequoia Pharmaceuticals, and president of oncology at Baxter Healthcare. In addition to Nutcracker Therapeutics, Ms. Collins currently serves as a board member at Certara, MaxCyte, DermTech, Alanis Therapeutics, Draper Laboratories, and Foundation for mRNA Medicines. About Nutcracker Therapeutics, Inc. Nutcracker Therapeutics, Inc. is a biotechnology CRDMO company that combines advanced engineering with high-precision biosynthesis to unlock the promise of RNA. The company’s mission is to drive forward the development of safe and effective RNA drugs and personalized cancer therapeutics through its complete technology platform, which encompasses the design, delivery, and manufacturing of RNA molecules. Armed with this high-tech advantage, Nutcracker Therapeutics’ unique scalable RNA platform significantly reduces costs and cycle times, while keeping the highest quality. For more information, visit www.nutcrackerx.com . SOURCE: Nutcracker Therapeutics

Samantha Budd Haeberlein, PhD, Joins the Board; Henrik Zetterberg, MD, PhD, Extends Advisory Role, Adding to a Preeminent Group of Multi-Disciplinary Experts Guiding ALZpath's Innovation Initiatives CARLSBAD, Calif., March 25, 2025 /PRNewswire/ -- ALZpath, Inc. (ALZpath), a leading developer of diagnostic tools and solutions for Alzheimer's disease and related dementias, announced the addition of Samantha Budd Haeberlein, PhD, to its board of directors and that Henrik Zetterberg, MD, PhD, a member of the company's advisory board, has been named Distinguished Science Advisor and will take a more active role guiding the company's innovation initiatives. Dr. Budd Haeberlein brings extensive experience to her role as director from the biopharmaceutical industry having served in senior management positions across neuroscience research, translational medicine, and clinical development functions at leading global companies, including Biogen and AstraZeneca. She currently serves as chief medical officer at Enigma Biomedical Group. She joins a board of directors with deep expertise across business, medicine, neuroscience, and pharmaceuticals. ALZpath Board Chair Jerre Stead said, "We are so pleased to have Samantha, who brings a wealth of experience in biotech, Alzheimer's disease, and in advanced treatment approaches for this devastating condition, as part of our board." Dr. Zetterberg became a member of the ALZpath advisory board in 2022, joining other distinguished leaders in Alzheimer's research who serve as advisors to ALZpath. He serves as a professor of neurochemistry at the University of Gothenburg, where he leads a group using neurochemical and molecular biology methodology to identify and study the pathophysiology of neurodegenerative diseases. In addition, Zetterberg serves as a professor of neurochemistry at University College London, where he leads the Institute of Neuroscience and Physiology. He holds an appointment at the University of Wisconsin Department of Medicine, School of Medicine and Public Health, has co-authored over 2,400 publications and is a member of the panel guiding the Alzheimer's Association Clinical Practice Guideline on the Use of Blood-based Biomarkers. ALZpath CEO, Mike Banville said, "We are extremely fortunate to have had Henrik – a world leader in neurochemistry and fluid biomarkers – involved as a key advisor for the past couple of years. As we enter the next phase of growth, we are eager for Henrik to play a more engaged advisory role. His experience will be increasingly valuable as more disease-modifying therapies become available to treat patients with Alzheimer's and other neurological conditions." Other members of the ALZpath Advisory Board include: Advisory Board Chair Jeff Cummings, MD, ScD(HC), Research Professor at the Department of Brain Health, Director, Chambers-Grundy Center for Transformative Neuroscience at University of Nevada, Las Vegas and Principal Investigator of the Biomarker Observatory for Alzheimer's Disease. Advisory Board Vice Chair Peter Snyder, PhD, Founding Editor-in-Chief for Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring Eric Reiman, MD, ALZpath Co-founder, CEO of Banner Alzheimer's Institute, Director of the Arizona Alzheimer's Consortium, Senior Scientist, Neurogenomics at the Translational Genomics Research Institute (TGen), Professor of Psychiatry at the University of Arizona, and University Professor of Neuroscience at Arizona State University Kaj Blennow, MD, PhD, Professor and Academic Chair in Clinical Neurochemistry at the University of Gothenburg, and head of the Neurochemistry Lab at Sahlgrenska University Hospital Jeff Dage, PhD, Senior Research Professor of Neurology, Primary Member, Stark Neurosciences Research Institute at Indiana University School of Medicine Sterling Johnson, PhD, Clinical Neuropsychologist at the University of Wisconsin-Madison School of Medicine and Public Health, Principal Investigator of the Wisconsin Registry for Alzheimer's Prevention (WRAP), and Co-PI of the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) Soeren Mattke, MD, DSc, Research Professor of Economics at University of Southern California (USC) and Director of the USC Brain Health Observatory Michael Weiner, MD, Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology at the University of California, San Francisco and Principal Investigator of the Alzheimer's Disease Neuroimaging Initiative (ADNI) and BrainHealthRegistry.org, Northern California Institute for Research and Education (NCIRE) About ALZpath ALZpath is a leading developer of innovative diagnostic tools and solutions for Alzheimer's disease and related dementias. Its award-winning ALZpath pTau217 antibody, integral to the most advanced and widely available blood-based tests, is transforming Alzheimer's disease research, diagnosis, treatment and monitoring. To accelerate the development of new medicines and improve patient care for millions, ALZpath democratizes access to its proprietary antibody through licensing agreements with leading global diagnostic and research organizations. These include Roche, Beckman Coulter, Bio-Techne, Alamar Biosciences, and Quanterix. Additionally, ALZpath partners with world-class laboratories, such as Neurocode, to further expand its reach and impact. To learn more about the company, please visit and follow us on LinkedIn. ALZpath Media Contact Nechama Rosengarten [email protected] SOURCE ALZpath, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

March 20, 2025Announcement no. 06 BioPorto announces the Annual Report for 2024 Copenhagen, Denmark, March 20, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today announces the annual financial results for 2024. Peter Mørch Eriksen, BioPorto’s Group Chief Executive Officer (CEO), comments It is with great enthusiasm that I reflect on the remarkable milestones achieved by BioPorto in 2024 – a year marked by significant accomplishments and strategic progress. We have focused on establishing a strong commercial platform. Our efforts have yielded promising results, including the first standing order from a US hospital and representation in 9 out of the top 10 best children's hospitals. These achievements are a direct result of the dedication of our employees, the unwavering support of our customers and collaborators, and the confidence our investors have in our growth strategy. Key strategic achievements for FY 2024 We strengthened our commercial setup, particularly in the US, by adding sales staff and medical liaisons to drive an increase in demand for NGAL products.A new partnership with Beckman Coulter, a leading global life sciences diagnostics innovator, was signed towards the end of the year, which expands our commercial reach and marks a key milestone.The first US standing order with a yearly value of more than USD 200,000.The ProNephro AKI (NGAL) study for adult use commenced in early 2024, with a goal to submit an application to the FDA by the end of 2026. Key milestones have been met, including the enrolment of the first patient ahead of schedule in October 2024.Successful completion of an oversubscribed direct issue of USD 11.7 million (DKK 81.4 million*) in June 2024. Financial highlights for FY 2024 Total revenue of DKK 36.2 million – a 17% growth compared to 2023.NGAL revenues in the US increased by 34% compared to 2023 – global NGAL revenues increased by 24% compared to 2023 and accounted for 64% of the total revenue.Adjusted EBITDA loss in 2024 amounted to DKK 70.6 million, which is in the middle of the revised guidance of DKK 68-73 million communicated January 6, 2025. 2024 2023 Change pct. DKK MILLION Revenue 36.2 31.0 17% Adjusted EBITDA loss 70.6 56.1 26% Cash and cash equivalents 59.7 66.4 -10% Guidance for 2025 As announced on March 19, 2025, BioPorto is targeting total revenue of DKK 45-60 million, corresponding to a growth in the range of 24-66% compared to 2024. Growth will be driven by increased ProNehro AKI (NGAL) sales, especially in the US. Revenue in 2025 is expected to be back-end loaded. For 2025, an adjusted EBITDA loss in the range of DKK 75-85 million is expected which corresponds to an increase of 6-20% compared to 2024. The higher expected loss is a result of higher sales and marketing costs for ProNephro AKI (NGAL) primarily in the US and the cost of clinical trials to support FDA clearance for ProNephro AKI (NGAL) for adults. Guidance FY 2025 Growth pct. DKK MILLION Revenue 45-60 24-66% Adjusted EBITDA loss 75-85 6-20% For 2026, BioPorto aspires to reach total revenue of DKK 80-125 million (app. USD 12-18 million). In addition, cash flow is expected to be positive and EBITDA neutral by the end of 2026 at the earliest. It is BioPorto’s aspiration to reach and exceed DKK 700 million (app. USD 100 million) in total revenue by 2029. The revenue growth will be contingent on the following key levers: Kidney damage biomarkers included in the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines in the first part of 2026.Entered strategic partnerships with the remaining three of the "Big 5" clinical chemistry instrument vendors, and ProNephro AKI (NGAL) commercialized on their key instruments.ProNephro AKI (NGAL) approved for adult use by FDA in 2027. *) DKK/USD Exchange Rate app. 7.00 To receive BioPorto’s Company Announcements, Press Releases, Newsletters and other business relevant information, please sign up on https://bioporto.com/investor-contact/. Webcast The Company’s management team will host a webcast today at 10:00 AM CET for investors and analysts to present the full year results following a Q&A session. The webcast is hosted by HC Andersen Capital, please register here to join the call. Investor Relations Contacts Hanne S. Foss, Head of Investor Relations, BioPorto, hsf@bioporto.com, C: +45 26368918 About BioPorto BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide. BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. Forward looking statement disclaimer Certain statements in this news release are not historical facts and may be forward-looking statements. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Company’s expectations, intentions and projections regarding its future performance including the Company’s Guidance for 2025; currency exchange rate fluctuations; anticipated events or trends and other matters that are not historical facts, including with respect to implementation of manufacturing and quality systems, commercialization of NGAL tests, and the development of future products and new indications; concerns that may arise from additional data, analysis or results obtained during clinical trials; and, the Company’s ability to successfully market both new and existing products. These forward-looking statements, which may use words such as “aim”, “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, and uncertainties that could cause the actual results of operations, financial condition, liquidity, dividend policy and the development of the industry in which the Company’s business operates to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given these risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Factors that may impact BioPorto’s success are more fully disclosed in BioPorto’s periodic financial filings, including its Annual Report for 2024, with the Danish Financial Supervisory Authority, particularly under the heading “Risk Factors”. Attachments 2025 03 20 - 2024 Remuneration Report - BioPorto AS 2025 03 20 - 2024 Annual Report - BioPorto AS BioPorto-2024-12-31-en